|
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
|
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
|
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab.
|
23182985 |
2013 |
|
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.
|
21228335 |
2011 |
|
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.
|
21228335 |
2011 |
|
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.
|
21228335 |
2011 |
|
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
|
21398618 |
2011 |
|
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
|
20921465 |
2010 |
|
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
|
20921462 |
2010 |
|
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
|
20921462 |
2010 |
|
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
|
20921462 |
2010 |
|
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
|
20921465 |
2010 |
|
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
|
20921465 |
2010 |
|
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
BRAF(V600E) efficient transformation and induction of microsatellite instability versus KRAS(G12V) induction of senescence markers in human colon cancer cells.
|
19881948 |
2009 |
|
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer.
|
19679400 |
2009 |
|
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.
|
19114683 |
2009 |
|
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer.
|
19679400 |
2009 |
|
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer.
|
19679400 |
2009 |
|
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.
|
19114683 |
2009 |
|
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.
|
19114683 |
2009 |
|
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.
|
18316791 |
2008 |
|
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.
|
18316791 |
2008 |
|
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.
|
18316791 |
2008 |
|
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.
|
16618717 |
2006 |
|
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.
|
16618717 |
2006 |